Company Analysis

Royalty Pharma plc (RPRX)

Nasdaq: RPRX · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2020
Grade6.3
◀ Past 6.5● Present 7.2▶ Future 5.0

Who runs Royalty Pharma plc

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Legorreta Pablo G.
CEO, Chairman of the Board. First filing Jun 2020, latest Nov 6, 2026, 5 filings in all.
Officers reporting now
6
of 14 people with a filing in the last fifteen months
Directors reporting now
8
22 people on the record since 2002
Officerssales are open-market, Nov 6, 2025 to Nov 6, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Legorreta Pablo G.CEO, Chairman of the BoardJun 2020Nov 6, 2026none
Hite ChristopherEVP & Chairman, PartneringJun 2020Nov 6, 20269 · $27.4M
Coyne Terrance P.EVP & CFOJun 2020Nov 6, 202635 · $39.0M
Urist MarshallEVP, Research & InvestmentsDec 2020Nov 6, 202618 · $12.5M
Mcgivern Arthur RichardEVP, Investments & GCJan 2026Jan 6, 2026none
Lloyd George W.EVP, Investments & CLOJun 2020Dec 19, 202511 · $13.8M
Directorssales are open-market, Nov 6, 2025 to Nov 6, 2026
NameRoleFirst filingLatest filingSales, 12 months
Bassler Bonnie LdirectorJun 2020Sep 30, 2026none
Coric VladdirectorApr 2025Jun 8, 2026none
Engelbert Catherine M.directorJun 2020Jun 8, 2026none
Ho CaroledirectorJul 2025Jun 8, 2026none
Hodgson David CdirectorJun 2022Jun 8, 2026none
Love Ted WdirectorAug 2020Jun 8, 2026none
Norden GregorydirectorJun 2020Jun 8, 20261 · $200,000
Weatherman Elizabeth HdirectorJul 2025Jun 8, 2026none
Earlier names on the record19, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton RPRX · research, not advice